AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer

被引:0
作者
Dirix, Luc [1 ]
Wildiers, Hans [2 ,3 ]
Huizing, Manon T. [4 ]
De Cuypere, Eveline [5 ]
Schroder, Carolina P. [6 ]
Armstrong, Anne C. [7 ]
Huober, Jans [8 ]
Marme, Frederik [9 ]
Schneeweiss, Andreas [10 ]
Khan, Sarah [11 ]
Triebel, Frederic [12 ]
机构
[1] Sint Augustinus, Antwerp, Belgium
[2] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium
[3] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium
[4] UZA, Breast & Gynaecol Oncol Unit, Antwerp, Belgium
[5] AZ Sint Jan Burgge Oostende AV, VZW Oncol Ctr, Brugge, Belgium
[6] Univ Med Ctr Groningen, Groningen, Netherlands
[7] Christie NHS Fdn Trust, Clin Med Oncol, Manchester, Lancs, England
[8] Univ Clin Women, Ulm, Germany
[9] Heidelberg Univ, Univ Clin Mannheim, Gynaecol Oncol, Mannheim, Germany
[10] Natl Ctr Tumor Dis, Heidelberg, Germany
[11] Notthingham Univ Hosp NHS Trust, Clin Oncol, Nottingham, England
[12] Immutep SAS, Res & Dev, Orsay, France
关键词
D O I
10.1158/1538-7445.SABCS19-OT1-01-05
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OT1-01-05
引用
收藏
页数:2
相关论文
empty
未找到相关数据